reports
GN Store Nord: 1 director
A director at GN Store Nord bought 7,000 shares at 201.500DKK and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Widodo Makmur Perkasa Tbk PT: 1 director
A director at Widodo Makmur Perkasa Tbk PT bought 375,000,000 shares at 15.000IDR and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
Arbona AB: 1 director
A director at Arbona AB sold 75,000 shares at 3.000SEK and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
Swire Pacific Ltd: 1 director
A director at Swire Pacific Ltd sold 527,500 shares at 10.747HKD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
GFL Environmental Inc: 1 director
A director at GFL Environmental Inc sold/sold after exercising options 86,820 shares at 44.920CAD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direc...
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences WEST CHESTER, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica Pharmaceuticals’ President and Chief Executive Officer, will present at the following investor conferences: RBC Capital Markets Global Healthcare ConferenceDate: Wednesday, May 15, 2024Time: 3:05 p.m. ETLocation: New York, NY HCW BioConnect Conferenc...
Whole Earth Brands Reports First Quarter 2024 Results
Whole Earth Brands Reports First Quarter 2024 Results CHICAGO, May 09, 2024 (GLOBE NEWSWIRE) -- Whole Earth Brands, Inc. (the “Company” or “we” or “our”) (Nasdaq: FREE), a global food company enabling healthier lifestyles through premium plant-based sweeteners, flavor enhancers and other foods, today announced its financial results for its first quarter ended March 31, 2024. First Quarter Highlights Consolidated revenue of $129.5 million, a decrease of 2.2% on a reported basis and 2.3% on a constant currency basis compared to the prior year period.Branded CPG revenue decreased 3.5% ...
Lexicon Pharmaceuticals to Participate in the Bank of America Securiti...
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024 THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced its participation in the Bank of America Securities Healthcare Conference 2024. Jeff Wade, Lexicon’s president and chief financial officer, will make a company presentation on Tuesday, May 14, 2024, at 8:00 am PDT (11:00 am ET). A simultaneous webcast will be available in the “Events” section of the Lexicon website at , and a recording of the webcast will be available for two weeks following the original...
Intellia Therapeutics Announces First Quarter 2024 Financial Results a...
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress Rapidly enrolling patients in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathyAligned with FDA on design for a new Phase 3 trial of NTLA-2001 for the treatment of hereditary ATTR amyloidosis with polyneuropathy, subject to review of IND application; expect to initiate the study by year-end Plan to present new clinical data from the ongoing NTLA-2001 Phase 1 in 2H 2024 On track to initiate the Phase 3 study of NTLA-2002 ...
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Resu...
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update Company to host a today at 8:30 a.m. Eastern Time NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia, and other central nervous system (CNS) diseases, today reported financia...
Kelly Reports First-Quarter 2024 Earnings
Kelly Reports First-Quarter 2024 Earnings Q1 operating earnings of $26.8 million, or up 34% on an adjusted basis Q1 revenue down following sale of European staffing operations; down 2.6% on an organic basis Q1 adjusted EBITDA margin increased 110 basis points to 3.2% driven by meaningful reduction in operating expenses resulting from business transformation initiatives and sale of European staffing operations Company expects further expansion of EBITDA margin from the planned Q2 2024 acquisition of Motion Recruitment Partners, LLC ("MRP") and ongoing transformation actions TROY, Mich., M...
Cronos Group Reports 2024 First Quarter Results
Cronos Group Reports 2024 First Quarter Results Industry-leading balance sheet with $855 million in cash and cash equivalents Net revenue in Q1 2024 increased by 30% year-over-year to $25.3 million Spinach® was top-3 in retail sales in Canada in the flower, edible, and vape categories in Q1 2024 Launched PEACE NATURALS® brand in the United Kingdom in May 2024 TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announces its 2024 first quarter business results. “Cron...
Sensei Biotherapeutics Reports First Quarter 2024 Financial Results an...
Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024 ASCO Annual Meeting - - Enrollment in the dose expansion portion of the clinical study advancing - - Strong balance sheet with cash runway into fourth quarter of 2025 - BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage imm...
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financ...
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results Completed oversubscribed $50 million private placement First participant dosed in clinical trial at University of Chicago Medicine assessing the use of tegoprubart to prevent islet cell transplant rejection in patients with type 1 diabetes Reported updated data from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation Tegoprubart used as part of immunosuppressive treatment following the first-ever kidney xenotransplant IRVINE, Calif., May 09,...
CorMedix Inc. Reports First Quarter 2024 Financial Results and Provide...
CorMedix Inc. Reports First Quarter 2024 Financial Results and Provides Business Update Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2024 and provided an update on its business. Recent Corporate Highlights: On April 2, 2024, CMS published its HCPCS coding decision for DefenCath...
Wave Life Sciences Reports First Quarter 2024 Financial Results and Pr...
Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update RestorAATion-2 clinical trial of WVE-006 in AATD patients underway; expected proof-of-mechanism data in patients with AATD remains on track for 2024 INHBE program for obesity expected clinical trial initiation in 1Q 2025; preclinical data demonstrate weight loss similar to semaglutide, fat loss with no loss of muscle mass, and curtailed rebound weight gain upon cessation of semaglutide, with potential for dosing 1 – 2 times per year Continued momentum in GSK collaboration; adva...
Cosa Resources Announces Summer Exploration Plans for Athabasca Basin ...
Vancouver, British Columbia--(Newsfile Corp. - May 9, 2024) - Cosa Resources Corp. (TSXV: COSA) (OTCQB: COSAF) (FSE: SSKU) ("Cosa" or the "Company") is pleased to announce its summer exploration plans for its portfolio of Athabasca Basin uranium projects.HighlightsDiamond drilling at Ursa to follow up positive winter drilling results and test second high priority target areaAmbient Noise Tomography (ANT) surveys to prioritize strike at Ursa and follow-up airborne survey results at OrionAirborne Electromagnetic (EM) and Gravity surveying at Aurora and Orbit to advance these shallow, prospectiv...
Eos Energy Enterprises Announces Participation in Upcoming Investor Co...
Eos Energy Enterprises Announces Participation in Upcoming Investor Conferences EDISON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. (NASDAQ: EOSE) ("Eos" or the “Company”), a leading provider of safe, scalable, efficient, and sustainable zinc-based long duration energy storage systems, today announced its participation at two upcoming investor conferences in June. Chief Executive Officer Joe Mastrangelo and Chief Financial Officer Nathan Kroeker will be attending and presenting at the Stifel Cross Sector Insight Conference in Boston on Wednesday, June 5, 2024. Mr...
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parki...
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its Phase III study of buntanetap in patients with early Parkinson’s disease (PD). Topline efficacy data is expected in June. The Phase III study was completed in 4Q 2023 with an original plan for data announcement in 1Q 2024, however the Compa...
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare...
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Tuesday, May 14, 2024 at 3:05 PM ET at the RBC Capital Markets Global Healthcare Conference, where members of management will also host investor one-on-one meetings. A live webcast and replay of th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.